| Nonpreemptive | Preemptive | p value |
---|---|---|---|
(n = 388) | (n = 153) | ||
Primary outcome | |||
 AUT (< MAP 70 mmHg)a | 14.5 ± 37.7 | 29.7 ± 61.0 | 0.002 |
Secondary outcomes | |||
 Inotropic use, n (%) | 54 (13.9) | 43 (28.1) |  < 0.001 |
 Vasopressor use, n (%) | 7 (1.8) | 15 (9.8) |  < 0.001 |
 Red blood cell transfusion, n (%) | 18 (4.6) | 17 (11.1) | 0.007 |
 Total volume of crystalloid, L | 3.1 (2.5, 3.6) | 3.1 (2.6, 3.7) | 0.127 |
 Total volume of synthetic colloid, L | 0.2 (0, 0.5) | 0.2 (0, 0.5) | 0.675 |
 Initial blood gas analysisb | |||
  Base excess, mmol/L | 0.6 (-1.9, 2.9) | -7.4 (-10.1, -4.9) |  < 0.001 |
  Serum bicarbonate, mmol/L | 24.7 (22.5, 26.7) | 18.1 (16.1, 19.9) |  < 0.001 |
  Serum sodium level, mmol/L | 136 (134, 138) | 137 (135, 139) |  < 0.001 |
  Serum potassium level, mmol/L | 4.1 (3.6, 4.6) | 4.1 (3.8, 4.6) | 0.673 |
  Serum calcium level, mg/dL | 1.0 (1.0, 1.1) | 1.0 (1.0, 1.1) | 0.914 |
Sodium bicarbonate use, mEq | 0 (0, 0) | 0 (0, 0) | 0.009 |